- Home
- REFI vs ZURA Comparison
REFI vs ZURA Comparison
Compare REFI & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | ZURA |
|---|---|---|
| Founded | 2021 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 252.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | REFI | ZURA |
|---|---|---|
| Price | $12.78 | $5.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $20.00 | $11.38 |
| AVG Volume (30 Days) | 150.4K | ★ 538.7K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | ★ 16.17% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $54,287,847.00 | N/A |
| Revenue This Year | $13.78 | N/A |
| Revenue Next Year | $4.07 | N/A |
| P/E Ratio | $7.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.85 | $0.97 |
| 52 Week High | $16.27 | $5.62 |
Technical Indicators
Market Signals| Indicator | REFI | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 75.99 |
| Support Level | $12.76 | $4.00 |
| Resistance Level | $13.20 | $4.44 |
| Average True Range (ATR) | 0.28 | 0.35 |
| MACD | -0.02 | 0.12 |
| Stochastic Oscillator | 10.86 | 80.88 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.